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Abstract: 150 words 
The Polo-like kinases (Plks) are an evolutionary conserved family of Ser/Thr protein kinases that 
possess, in addition to the classical kinase domain at the N-terminus, a C-terminal polo-box 
domain (PBD) that binds to phosphorylated proteins, modulates the kinase activity and its 
localization. Plk1, which regulates the formation of the mitotic spindle, has emerged as a 
validated drug target for the treatment of cancer, because it is required for numerous types of 
cancer cells but not for the cell division in non-cancer cells. Here, we employed chemical biology 
methods to investigate the allosteric communication between the PBD and the catalytic domain 
of Plk1. We identified small compounds that bind to the catalytic domain and inhibit or enhance 
the interaction of Plk1 with the phosphorylated peptide PoloBoxtide in vitro. In cells, two new 
allosteric Plk1 inhibitors affected the proliferation of cancer cells in culture and the cell cycle, but 
had distinct phenotypic effects on spindle formation. Both compounds inhibited Plk1 signaling 
indicating that they specifically act on Plk1 in cultured cells.  
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Introduction 
Protein kinases are a large family of proteins comprising an evolutionary conserved catalytic 
domain 
1
. Protein kinases function like molecular switches regulating a large set of signaling 
pathways 
2
. The whole family has therefore evolved very precise and specific mechanisms to 
regulate their activities 
3
, to properly transfer signals and to respond to the requirements of the 
cells at the appropriate cellular location and the right time. The Polo-like kinase 1 (Plk1) is 
conserved throughout eukaryotic organisms, locating during the cell division at the mitotic 
spindle triggering the G2/M phase of the cell cycle and participating in the segregation of 
chromosomes to the two daughter cells.  
Human Plk1 comprises a catalytic domain followed by a polo box domain (PBD) (Figure 1A). 
Inhibitors of Plk1 cause cell cycle arrest at G2/M followed by the induction of apoptosis in a 
variety of cancer cell types. An increasing number of Plk inhibitors has been developed for the 
treatment of cancer patients. One ATP-binding site inhibitor, BI6727, received FDA 
Breakthrough Therapy designation for treatment of patients suffering from acute myeloid 
leukemia (AML). Since all protein kinases share similarities at the ATP-binding site, this type of 
inhibitor frequently inhibits many other protein kinases 
4
, leading to off-target side effects in 
patients. Alternatively, targeting the mechanism of regulation of protein kinases can lead to very 
selective inhibitors that may be more suitable for combination therapies and long-term 
treatments. 
Plks are regulated by PBD-mediated localization, by phosphorylation, by ubiquitination and by 
an intramolecular interaction between the catalytic domain and the PBD. The crystal structure of 
the catalytic domain has been solved in complex with ATP-competitive inhibitors, i.e. BI6727 
5
 
and the PBD has been investigated by crystallography, thereby depicting the molecular details of 
the interaction with phosphorylated polypeptides 
6
. More recently the structure of the Plk1 from 
Danio rerio (zebrafish) showed how the PBD interacts and inhibits the catalytic domain 
7
. 
Binding of phosphorylated polypeptides to the PBD both, regulates the subcellular localization / 
co-localization with substrates and activates the kinase domain 8 (see scheme in Figure 1 B,C). 
Phosphorylation at T210 is also important for the regulation of the activity of Plk1. Low 
molecular weight inhibitors that bind to the PBD of Plk1 have been identified 
9-12
. Together, the 
derived model of Plk1 regulation supports the existence of a dynamic allosteric mechanism of 
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regulation which may be modulated by small compounds, as identified earlier in other protein 
kinases 
13, 14
. Here we use the terminology “allostery” and “allosteric” to refer to the biochemical 
phenomenon where the binding of a macromolecular partner or a small-molecule ligand at one 
location leads to specific perturbations at a site not in direct contact with the region where the 
binding occurs 
15, 16
. This definition differs from a frequent usage of the terminology in the 
protein kinase field where “allosteric” refers to a compound that binds at a site different from the 
ATP-binding site, independently of a known effect at a distant site. 
In the present work we investigated the allosteric mechanism of Plk1 regulation using a chemical 
biology approach. We identified compounds that enhance or inhibit the interaction of Plk1 with 
the phosphorylated polypeptide that binds to the PBD. Two of the compounds, FM00204 and 
SCR01010, disrupted Plk1 localization and inhibited Plk1 function in cells. Our work describes 
aspects of the allosteric communication between the PBD and the catalytic domain of Plk1 in 
vitro and its effects in cells, indicating a fundamental role of the proper PBD-driven dynamic 
modulation of the conformation of Plk1 in cells and validating new allosteric drug development 
approaches to Plk1. 
 
Results and Discussion 
Identification and in vitro characterization of small compound allosteric modulators of Plk1 
The intrinsic protein kinase activity of Plk1 can be measured using a polypeptide substrate 
(KKGGSFNDTLDFD) derived from Lansing et al. 
17
. The assay allows measuring the intrinsic 
kinase activity of the catalytic domain of Plk1 and the effect of compounds that may affect the 
catalytic domain. In this in vitro assay, the characteristic phosphorylated polypeptide derived 
from the Plk1 substrate Cdc25 that binds to the PBD, PoloBoxtide (MAGPMQST(P)PLNGAK), 
activated Plk1 as described 
8
 (Figure 1D).  
To analyze the allosteric mechanisms that can modulate Plk1 conformation and activity, we set 
up an AlphaScreen homogeneous assay measuring the interaction between PoloBoxtide and full 
length Plk1 (see scheme in Figure 1E). The conditions were designed such that the assay could 
identify enhancers or inhibitors of the interactions (see Materials and Methods and Supporting 
Information). We then screened a collection of 1280 approved drugs and molecular probes. We 
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identified that the flavonoid luteolin enhanced the interaction between PoloBoxtide and Plk1 
(AC50 20 M; Figure 1F). In an overall similar approach, we established the assay measuring the 
interaction between PoloBoxtide and the isolated PBD (see scheme in Figure 1G). Luteolin did 
not affect the interaction between PoloBoxtide and the PBD (Figure 1H). A compound exposing 
the PBD for interaction with PoloBoxtide would be expected to release the intramolecular 
inhibition in Plk1 and be an “activator”. However, Luteolin had been previously found to bind at 
the ATP-binding site of the protein kinase CK2 
18
. NMR-based ligand observed waterLOGSY 
(WL) experiment was used to investigate the interaction of the small molecule with the Plk1 
kinase domain. WL is based on detecting the transfer of magnetization from the bulk solvent to 
the small solute (ligand) molecules. The sign of the ligand (small molecule) signal is inverted (or 
an increase in the intensity) when the ligand is bound to a slowly tumbling macromolecule 
(protein) within the sample. The presence of positive signals for the proton resonances (SI Figure 
1C, signals (*)) of Luteolin in the WL spectrum acquired in the presence of both ATP-analogue 
and Plk1 kinase domain indicated binding to the protein. The proton signals of AMP-PNP (a non-
hydrolyzable analogue of ATP)  (SI Figure 1C, signals marked 2) displayed negative intensities 
and were comparable to the intensities observed in the absence of protein (SI Figure 1A, signals 
marked 2), suggesting that AMP-PNP did not bind in the presence of luteolin. These results 
confirmed that Luteolin binds to the Plk1 kinase domain and competes out AMP-PNP from its 
binding site. Luteolin inhibited the activity of Plk1 towards a polypeptide substrate which does 
not require a PBD docking interaction (IC50 5.8 M; Figure 1I). This is in agreement with 
luteolin binding at the ATP-binding site of Plk1, as described to bind to CK2 
18
. Interestingly, 
together, the above results suggested that the binding at the ATP-binding site produced allosteric 
effects that enhanced the binding of the PBD to PoloBoxtide. The above data provided 
experimental evidence of the rich allosteric communication between the PBD and the catalytic 
domain, which could be modulated by small compounds.  
To identify new allosteric modulators of Plk1, we then screened a library comprising 14400 small 
compounds (average size 320 Da) for their ability to affect the interaction between PoloBoxtide 
and full-length Plk1. We identified a number of small molecules which inhibited or increased to 
different degrees the interaction of Plk1 with PoloBoxtide. Here, we present compounds 
AW00551, SCR01010 and FM00204 (Figure 2A), that exhibited two different allosteric effects. 
While FM00204 enhanced the interaction between full-length Plk1 and PoloBoxtide (Figure 2B; 
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AC50= 10 M), SCR01010 and AW00551 weakened the interaction between PoloBoxtide and 
full-length Plk1 (Figure 2B; IC50= 20 M and 1 M, respectively). We tested the effect of the 
compounds on the interaction between PoloBoxtide and the isolated PBD of Plk1. None of the 
compounds effected the interaction between the PBD and PoloBoxtide (Figure 2C), indicating 
that their effects were not by direct competition with PoloBoxtide.. Further, using the WL 
experiment we probed the binding of AW00551, SCR01010 and FM00204 to the isolated Plk1 
kinase domain. SCR01010 was insoluble under the NMR experimental buffer conditions. WL 
spectra of FM00204 and AW00551 in the presence of AMP-PNP and Plk1 kinase domain 
showed positive signals (SI Figure 2C and 2D, signals (*)) for the compounds and negative for 
AMP-PNP (SI Figure 2C and 2D, signals marked 2).  In addition, we tested the possible binding 
of FM00204 and AW00551 to the isolated PBD (SI Figure 3A). FM00204 did not bind to the 
PBD. In contrast, a waterLOGSY NMR experiment clearly detected an interaction between 
AW00551 and the isolated PBD of Plk1 (SI Figure 3B). Thus, we suggest that AW00551 
interacts with both, the catalytic domain and the PBD (SI Figure 4C). 
Further, the compounds partially inhibited the enzymatic activity of full-length (FL) and of the 
catalytic domain (CD) of Plk1 (Figure 2D), although the potency for the inhibition of Plk1 
activity in vitro was very low. Such low potency in vitro is not expected to inhibit the cellular 
kinase activity significantly by interaction with the ATP-binding site of the kinase stabilized in an 
active conformation in the presence of at least ten times higher concentration of ATP. However, 
the compounds could inhibit Plk1 downstream signaling in cells by allosteric mechanisms, for 
example, by affecting the ability of the PBD to interact with cellular partners at precise cellular 
complexes. 
To further describe the mechanism by which the small compounds affected the binding of Plk1 to 
PoloBoxtide, we next investigated the effect of the compounds on the temperature stability of 
Plk1 and on the isolated catalytic domain of Plk1. As a control, we tested the effect of BI6727 on 
the temperature stability of Plk1. Interestingly, we found that the ATP-competitive inhibitor 
BI6727 strongly stabilized the catalytic domain of Plk1 (Tm= 20.8  0.02 °C; Figure 2E) but 
was overall destabilizing the full-length protein (Tm= -11.77  0.95 °C; Figure 2F). Indeed, in 
the presence of BI6727 the graphical representation of denaturation of full-length Plk1 by 
temperature revealed a complex denaturation pattern, with two distinct denaturation curves. A 
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first curve revealed that BI6727 de-stabilized Plk1 (Tm of -11.1 °C) while the second portion of 
the curve revealed a stabilization of a portion of Plk1 by approximately 6.6 °C (Figure 2F). Since 
BI6727 stabilized the catalytic domain we interpreted that the de-stabilization should be mediated 
by the PBD. One possibility was that the binding of BI6727 would release the intramolecular 
interaction between the catalytic domain and the PBD and “open” the structure of Plk1, therefore 
facilitating the denaturation of the PBD. We reasoned that if this was the case, the release of the 
PBD would enhance the interaction with PoloBoxtide. Indeed, BI6727 enhanced the interaction 
of PoloBoxtide with Plk1 (Figure 2G). Together, the finding indicated that BI6727, like luteolin, 
allosterically promoted the open-active structure of Plk1, enhancing the interaction with 
phosphorylated polypeptides substrates of Plk1; thus, BI6727 exposes the PBD for interaction 
with interacting partners, enhancing the open-active conformation and at the same time potently 
inhibiting Plk1 catalytic activity.  
FM00204 did not significantly affect the overall stability of full-length Plk1 and only mildly 
stabilized the catalytic domain (Tm 1.8  0.25 °C) suggesting that it also binds to the catalytic 
domain of Plk1 and that, in full-length Plk1, by displacing the PBD interaction with the catalytic 
domain (see scheme in Figure 2H), it produces a mix of stabilization of the catalytic domain and 
de-stabilization of the full-length protein, which are substracted. AW00551, on the other hand, 
stabilized the full length Plk1 protein (Tm 4.98  0.7 °C) whereas it also stabilized the catalytic 
domain (Tm 2.51  0.09 °C). Such behavior is consistent with AW00551 binding at least 
partially to the catalytic domain and stabilizing the inhibited form of Plk1, with the PBD attached 
to the catalytic domain, inhibiting the binding to PoloBoxtide (see scheme in Figure 2H). 
SCR01010 could also have such mechanism of action since it inhibits the interaction with 
PoloBoxtide; however, we could not evaluate the effect of SCR01010 on the Plk1 stability assays 
because the compound precipitated under the conditions of the assay. The above characterizations 
showed that the conformation of Plk1 can be modulated by allosteric compounds, i.e. binding of 
the compounds to the catalytic domain can enhance or inhibit the interactions of the PBD with its 
phosphorylated binding partners, including substrates.  
In order to gather additional information on the molecular mechanism of action of the three 
compounds we checked their ability to inhibit the in vitro the kinase activity of a panel of 50 
protein kinases (Table S1). At 20 M, FM00204 inhibited more then 50% the activity of 7 out of 
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50 protein kinases in the panel. Since NMR data showed that FM00204 competes out an ATP-
analogue, we can suggest that FM00204 binds at the ATP-binding site (Figure 3B). The poor 
selectivity of FM00204 is in agreement with FM00204 binding at the ATP-binding site in the 
active conformation of the kinase, and partially inhibiting different kinases with low potency 
(Figure 3B). In comparison, SCR01010 inhibited one kinase in the panel and AW00551 only 
inhibited Plk1. The NMR indicated that AW00551 binds both to the isolated catalytic domain and 
to the isolated PBD of Plk1; in addition, the NMR data indicated that the binding of AW00551 
competed out the ATP-analogue. Therefore we suggest that AW00551 may bind to the catalytic 
domain and the PBD in a manner that allosterically communicates with the ATP-binding site, 
stabilizing the inactive structure of the ATP-binding site (option 1; Figure 3C). Since the crystal 
structure of the zebrafish Plk1 shows the PBD in direct proximity to the inactive structure of the 
ATP-binding site 
7
, the compound could also bind at such site (option 2, Figure 3C). Since NMR 
experiments indicated that the binding of all compounds competed out ATP, the mechanism of 
inhibition is expected to be due to the lack of ATP binding and not to a modification of the Km 
for ATP. We also tested if the compounds would excert their effects on a Plk1 protein that is 
mutated at the ATP-binding site. Mutations at the ATP-binding site could affect the overall 
conformation of the kinase. Therefore, for this assay, we employed Plk1 [Cys67Val; Leu130Gly], 
a construct that has two mutations at the ATP-binding site and was shown to conserve its 
physiological functions, but has modified sensitivity to compounds binding at the ATP-binding 
site 
19
. GFP-Plk1 wt bound to biotin-PoloBoxtide and the interaction was greatly enhanced by 
BI6727 and FM00204 while the interaction was robustly inhibited by AW00551 and SCR01010. 
GFP-Plk1 [Cys67Val; Leu130Gly] also bound biotin-PoloBoxtide, however, the interaction was 
not affected by BI6727 or FM00204 (SI Figure 4). The finding confirmed that FM00204, like 
BI6727, indeed bind to the ATP-binding site. However, AW00551 and SCR01010 also inhibited 
to some degree the interaction of biotin-PoloBoxtide with GFP-Plk1 [Cys67Val; Leu130Gly]. 
Therefore the binding site of AW00551 and SCR01010 remained undefined between option 1 
and option 2 shown in Figure 3. 
In previous work we showed how the interaction of substrates at a docking site on the protein 
kinase PDK1 can regulate the activity of the catalytic domain by allosterically affecting the 
conformation of the ATP-binding site 20-22. Interestingly, we also described compounds binding at 
the ATP-binding site on PDK1, which can modulate the conformation of the docking site, by the 
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reverse allosteric path 
23
. Indeed, the bi-directionality is an intrinsic characteristic of allosteric 
systems. Similarly, important allosteric effect induced by compounds binding at the ATP-binding 
site have also been described in other protein kinases such as IRE1 where different inhibitors 
enhance or inhibit its RNAse activity  
24
 and RAF, where the binding of an inhibitor to one 
partner in a dimer results in the activation of the other molecule in the dimer 
25, 26
. In an 
analogous manner, we suggest that the PBD inactivates the kinase by stabilizing the ATP-binding 
site of Plk1 in an inactive conformation, and that BI6727 and FM00204 produce the reverse 
allosteric effect, binding at the ATP-binding site and displacing the intramolecular interaction 
with the PBD (Figure 3A,B). The compounds FM00204 and AW00551 have an allosteric 
mechanism of action because they bind to a given site on the catalytic domain and allosterically 
affect the interaction to PoloBoxtide, at a distant site. On the other hand, compounds with a mode 
of action as depicted option 1 in Figure 3C are also allosteric because they bind at a distant site 
and allosterically affect the conformation of the ATP-binding site. 
FM00204 and SCR01010 influence the interaction of Plk1 with Bora and the 
phosphorylation of substrates in cells 
Hit compounds identified in an in vitro screening using pure components may be inactive or non-
specific in cells. Luteolin was potently inhibiting cellular proliferation but we could not identify a 
primarily effect on Plk1   In contrast, we identified that FM00204 and SCR01010 selectively 
affected Plk1 signalling and were characterized in depth. Plk1 is activated by Aurora A, which 
phosphorylates Plk1 at T210 in G2. This phosphorylation event requires the presence of the co-
factor Bora 27, 28. To examine the effect of compounds on a specific Plk1 protein-protein 
interaction, we synchronized cells in mitosis by Nocodazole treatment and probed the effects on 
the Plk1/Bora complex  (Figure 4A). To study the Plk1/Bora interaction, we immunoprecipitated 
Plk1 and analyzed the amount of Bora that co-immunoprecipitated. Interestingly, the Plk1/Bora 
interaction was blocked by SCR01010 and augmented by FM00204 (Figure 4B) supporting the 
model that the allosteric compounds SCR01010 and FM00204 influenced the three-dimensional 
structure of Plk1 and modulated the ability of Plk1 to form complexes in a cellular setting. 
Next, we studied the effect of compounds on specific Plk1 substrates (TCTP, Myt1, the 
cdc2-activating phosphatase Cdc25c) in compound-treated cells. The translationally controlled 
tumor protein TCTP was identified as a protein that binds to the PBD of Plk1 
29
. Subsequently, 
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Plk1 phosphorylates TCTP on two serine residues.  In addition, Plk1 phosphorylates Myt1, an 
inhibitory kinase for the MPF, and the phosphatase Cdc25c during M phase 
30, 31
. Since FM00204 
was shown to enhance the interaction between full-length Plk1 and PoloBoxtide (Figure 4B), we 
analyzed the phosphorylation of TCTP, Cdc25c and Myt1 by Plk1 using phospho-specific 
antibodies. Interestingly, in the presence of FM00204 we observed an increase of Plk1–specific 
phosphorylation of all three proteins (Figure 4C). Remarkably, the phospho-peptide, 
PoloBoxtide, used for the assays depicted in figure 2 represents the binding site for Plk1 in 
Cdc25c. We could demonstrate that FM00204 promotes not only the binding of PoloBoxtide to 
full-length Plk1, but also the phosphorylation of Cdc25c which might suggest improved binding 
of Cdc25c and Plk1 in cells. 
In contrast, in cells treated with SCR01010, that reduces the binding of  PoloBoxtide to full-
length Plk1 (Fig. 2B), a decreased phosphorylation of Myt1 was observed (Figure 4C). The 
phosphorylation of TCTP and Cdc25C remained below the limit of detection. Although both 
compounds, SCR01010 and FM00204, had a weak inhibitory effect on Plk1 catalytic activity in 
vitro, the augmented binding of the substrate proteins TCTP, Myt1 and Cdc25c seemed to be 
sufficient for their enhanced phosphorylation by Plk1.  
 
FM00204 and SCR01010 inhibit cell proliferation by arresting cells in G2/M and promoting 
apoptosis 
Owing to the essential role of Plk1 in mitosis 
32, 33
 it is expected that interfering with its function 
using small molecule inhibitors would generate a mitotic arrest accompanied by an increase in 
mitotic index. Measurements by flow cytometry revealed that the treatment of HeLa cells with 
SCR01010 and FM00204 increased the proportion of mitotic cells (SI Figure 5A). While 
SCR01010 (25 μM) induced a mitotic arrest of 34%, the treatment with 25 μM FM00204 arrested 
80% of the cells in G2/M (SI Figure 5A). The induction of a mitotic arrest by both compounds 
was confirmed in western blot analyses demonstrating an increase of hyperphosphorylation of 
Cdc25c, a characteristic feature of mitotic cells (SI Figure 5B). Furthermore, we observed an 
increase in the levels of the mitotic markers Plk1, Cyclin B1 and phosphohistone H3 (SI Figure 
5B). SCR01010 and FM00204 inhibited the proliferation of HeLa cells in a dose-dependent 
manner (SI Figure 5C). Cancer cells with inhibition of Plk1 undergo apoptosis, mostly caused by 
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mitotic catastrophe. To corroborate that inhibiting Plk1 function triggers cancer cells to 
apoptosis, asynchronous HeLa cells were treated with increasing amounts of both compounds for 
24 hours. Indeed, we found a dose-dependent increase in apoptosis induction by annexin staining 
(SI Figure 5D).  
The inhibition of Plk1 in cells can be followed by studying the phenotype of treated cells 
using immunofluorescence microscopy (Figure 5A). The phenotypes induced by FM00204 and 
SCR01010 were compared to those generated by the ATP-competitive inhibitor BI6727 
5
 and 
Poloxin 
9
. FM00204 (20 M) and SCR01010 (20 M) caused a prometaphase arrest associated 
with a mitotic index of 58% and 42%, respectively compared to 14% for Poloxin (20 M) and 
59% for BI6727 (100 nM) (Figure 5A,B). SCR01010 and FM00204 displayed different effects on 
mitotic spindles. SCR01010 generated mainly aberrant, thin and small spindles (57%), which 
were to some degree comparable to a Poloxin-induced phenotype (Figure 5 A,C). On the other 
hand, FM00204 showed an accumulation of multipolar spindles (45%) (Figure 5 AD). Moreover, 
we could confirm the findings of several studies reporting that BI6727, at a concentration of 100 
nM, generates exclusively monopolar spindles (Figure 5 A,E). The different phenotypes 
generated by SCR01010 and FM00204 suggest different mechanisms of action of Plk1 inhibition 
implicated in spindle nucleation and centrosome maturation or separation during early mitotic 
phases 
34-36
. The effects of SCR01010 and FM00204 on chromosome dynamics were also 
examined by immunofluorescence. Similar to Poloxin or to BI6727, both compounds SCR01010 
and FM00204 generated a high rate of chromosome congression failure following 16 h after the 
treatment, up to 73%, 100%, 78% and 58% respectively for Poloxin, BI6727, SCR01010 and 
FM00204 (Figure 4 A,F). 
Plk1 allosteric modulators affect the cellular localization of Plk1 
The PBD of Plk1 is known to be required for Plk1 localization at centrosomes and kinetochores 
during mitosis. The PBD is proposed to mediate this task by docking to phosphorylated sites 
generated by other priming kinases 
8, 37
. However, it has also been reported that the kinase 
activity is also involved in Plk1´s mitotic sub-localizations by generating its own phosphosites for 
PBD binding (self-priming) 
38, 39
. We therefore sought to investigate whether SCR01010 and 
FM00204 affect the localization of Plk1 during early phases of mitosis. Thus, we stained HeLa 
cells with γ-Tub and with the anti-centromere antibody ACA as centrosome and centromere 
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marker. Whereas control mitotic HeLa cells showed a clear centrosome and kinetochore 
localization of Plk1, all other treatments led to its partial removal from centrosome and 
kinetochores. The strongest mislocalization of Plk1 from centrosomes and kinetochores was 
achieved after treating cells with SCR01010 (42%). The mislocalization induced by treatment 
with Poloxin (32%) or FM00204 (31%) was less pronounced (Figure 5 G,H). Eventhough a high 
number of BI6727-treated cells showed the presence of Plk1 at centrosome and kinetochore, this 
signal was very weak and faint compared to control cells (Figure 5 F,H). Intriguingly, treating 
cells with SCR01010 or FM00204 produced large Plk1 aggregates, that were seen either in 
proximity to the DNA or even outside the chromosomal zone, which indicates that these large 
foci were unlikely the result of abnormal kinetochore recruitment of Plk1 (Figure 5G, white 
arrow heads). A similar observation of large Plk1 aggregates was made when cells were treated 
with Poloxin or BI6727 but only to a lesser extent (Figure 5G). These data confirm that 
SCR01010 and FM00204 trigger similar phenotypes as those generated by the established Plk1 
inhibitors (Poloxin and BI6727) and strongly argue for the specificity of these two new 
compounds toward Plk1. 
Together, the present work describes the allosteric modulation of Plk1 by small compounds. Our 
results suggest that the effect of inhibiting the cellular function of Plk1 may be equally observed 
by compounds that potently inhibit the enzymatic activity of Plk1 or by allosteric modulators that 
are weak inhibitors of Plk1 enzymatic activity. SCR01010 and FM00204 specifically inhibited 
Plk1 function in cells by affecting the conformation and mechanism of regulation of Plk1, 
enhancing or inhibiting the binding to phosphorylated epitopes that participate in the dynamic 
proper localization of Plk1. BI6727, luteolin and FM00204 open the structure of Plk1 thereby 
releasing the inhibition that the PBD exerts on the catalytic domain. In addition, BI6727 potently 
inhibits the catalytic activity of Plk1. In contrast, the mechanism of action of AW00551 and 
SCR01010 appear to produce a different set of effects, inhibit the binding to phosphorylated 
epitopes to the PBD and stabilize the PBD-catalytic domain interaction that physiologically 
inhibits Plk1. Such mechanism could explain how compounds with different mode of action 
produce different effects on cells. Interestingly, we describe here that the effect of SCR01010 and 
FM00204 is to disturb the proper intermolecular interactions of Plk1 and promote mislocalization 
of Plk1. In these cases, by mislocalizing the kinase, the inhibition of physiological function of 
Plk1 could last for longer periods of time after the compound has dissociated from Plk1. 
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Although BI6727 received FDA breakthrough designation, still, it has not been very successful in 
the clinic. One reason might be that ATP-competitive Plk1 inhibitors also target the tumor-
suppressor proteins Plk2 and Plk3. Inhibitors binding at a site different from the ATP-binding site 
can be more specific and are clear alternatives to minimize side effects of protein kinase 
inhibitors 
14
. Moreover, the effects on the patient may be different if the inhibitors did not 
enhance but inhibited the Plk1 interactions mediated by the PBD. Thus, the effect of Plk1 
inhibitors on the formation of protein complexes may be relevant to improve the outcome of the 
therapies of cancer patients.  
We suggest that SCR01010 and FM00204 could provide alternative mechanisms for the 
development of selective allosteric drugs to Plks, for the treatment of cancers. Together, we here 
describe a set of small compounds, molecular probes, that have diverse allosteric mechanisms of 
action, modulating the conformation of Plk1 in different ways. It is suggested that the different 
compounds modulators of the conformation of Plk1 could produce different on-target effects with 
differential effects on cancer therapeutics. 
 
 
Materials and Methods 
Details on the proteins used, the AlphaScreen interaction assays, the screening of libraries, the in 
vitro kinase activity assay, the temperature stability assay and cell-based assays are presented 
under Supporting Information. In brief, GST-His-Plk1 FL was from ProQinase; His-Plk1 FL and 
His-Plk1 CD (13-345) were produced from pTriEX1.1 vector in insect cells. His-PBD was 
produced in bacteria as described 
10
. NMR methods are described in the text and in the 
Supplementary Information. The interaction assays were performed using the AlphaScreen 
technology following the general guidelines of the manufacturers (Perkin Elmer). The interaction 
assay contained 30 nM Plk1 and 50-100 nM PoloBoxtide in 50 mM Tris-HCl (pH 7.4), 100 mM 
NaCl, 2 mM dithiotreitol, 0.01% (v/v) Tween-20 and 0.1% (w/v) BSA. The screened libraries (50 
M) were the FDA-approved library (Prestwick) and a library comprising 14400 diverse 
compounds (Hiftinder, from Maybridge). The individual compounds in the library have been 
analyzed by the manufacturer by appropriate methodologies including NMR, FT-IR, LC-MS, 
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HPLC and elemental analysis, with greater than 90 % purity, with majority of compounds with 
more than 95 % purity; reactive compounds are excluded from the Hitfinder library. Individual 
compounds were purchased from Maybridge. Compounds subjected to NMR studies were 
confirmed to have high purity and the expected chemical features. The Plk activity assay was 
performed in a mix containing 50 mM Tris-HCl pH 7.5, 0.05 mg/ml BSA, 0.1% (v/v) 2-
mercaptoethanol, 10 mM MgCl2, 100 μM [γ
32
P]ATP (5–50 cpm/pmol), 0.003% Brij, 150-350 ng 
GST-His-Plk1, and the peptide substrate (KKGGSFNDTLDFD, 100 μM) as performed for other 
kinases 
22
. Temperature stability assays were performed using the differential scanning 
fluorimetry as previously performed 
21
. Cell-based assays were performed using standard 
protocols 
40
. Unless specified otherwise, experiments were performed at least in triplicate. 
Statistics were analyzed by Student’s t-test (two-sided, paired). Significant differences are 
indicated with an asterisk (*P≤0 05; **P≤0 01; ***P≤0 001)  
Supporting Information is available, including Supplementary methods, SI Table 1 and SI Figure 
1-5. This material is available free of charge via the internet at http://pubs.acs.org. 
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Figure legends 
 
Figure 1. Mechanism of regulation  of Plk1 by interaction of phosphopeptide with the PBD 
domain and screening for compounds that modulate the interaction. (A) Representation of the 
linear structure of Plk1, consisting of an N-terminal protein kinase catalytic domain and a C-
terminal PBD domain. (B) Representation of the inhibited form of Plk1. The PBD domain folds 
onto the catalytic domain, inhibiting the catalytic activity. (C) Representation of the activated 
form of the kinase. The phosphopeptide PoloBoxtide binds to the PBD domain and releases the 
intramolecular interaction that inhibits the kinase. (D) PoloBoxtide activates Plk1 in vitro. (E) 
interaction between full length Plk1 and PoloBoxtide using the alphascreen technology. Upon 
excitation, the donor beads –D- produces oxygen singlets; if the two partners interact, the oxygen 
singlet excites the acceptor bead –A- that produces light. This homogeneous assay was used to 
screen for compounds that modulate the interaction. (F) Interaction between PoloBoxtide and the 
isolated PBD domain of Plk1 using AlphaScreen. (G) Luteolin, enhances the interaction between 
Plk1-FL and PoloBoxtide in vitro. (H) Luteolin does not affect the interaction between 
PoloBoxtide and the isolated PBD domain. (I) Luteolin inhibited the catalytic activity of Plk1, 
presumably by binding to the ATP-binding site and directly competing for the binding of ATP. 
Values represent the mean ± the standard deviation (SD). 
Figure 2. In vitro characterization of small compounds that modulate the conformation of Plk1, 
enhancing or inhibiting the interaction with PoloBoxtide. (A) Chemical structures of compounds 
identified in the screening of a library of a diverse set of small compounds. (B) Effect of small 
compounds on the interaction between Plk1 and PoloBoxtide. (C) Effect of small compounds on 
the interaction between PoloBoxtide and the isolated PBD domain of Plk1. (D) Effect of small 
compounds on the in vitro kinase activity of Plk1 full-length (FL) and on the isolated catalytic 
domain (CD) of Plk1. (E) Denaturation of Plk1 CD by temperature and stabilization by BI6727.  
(F) Denaturation of Plk1 FL by temperature and the effect of BI6727 on the stability. (G) BI6727 
enhances the interaction between Plk1 FL and PoloBoxtide. (H) Schematic representation of the 
mechanism of action of small compounds that modulate the exposure of the PBD. Left, BI6727 
binds to the ATP-binding site on the catalytic domain and potently inhibits the catalytic activity; 
in addition, our results indicate that BI6727 releases the intramolecular interaction with the PBD 
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domain, which in turn, binds more efficiently to PoloBoxtide. Center, compound FM00204 binds 
at the catalytic domain and releases the intramolecular interaction with the PBD domain. Right, 
compounds AW00551 and SCR01010 stabilize the intramolecular interaction of the PBD domain 
with the catalytic domain. Values represent the mean ± the standard deviation (SD). 
 
Figure 3. Schematic model on the proposed allosteric communication between the polo-box 
domain and the catalytic domain in Plk1 by BI6727, FM00204 and SCR01010/AW00551. (A) 
BI6727 binds to the ATP-binding site on the catalytic domain of Plk1, opens the Plk1 structure, 
enhancing interaction of PBD with phosphorylation-dependent interactions, stabilizing 
interactions with substrates and PBD-dependent molecular complexes, possibly affecting the 
proper dynamic localization of Plk1. In the right side of the panel, ATP is shown in red. Besides 
stabilizing the “open-active” structure, BI6727 is a high affinity inhibitor and therefore displaces 
ATP from the ATP-binding site. In this manner, BI6727 affects the dynamic proper location of 
Plk1 and also inhibits the cellular phosphorylation of all substrates. (B)  FM00204 binds to the 
catalytic domain of Plk1 producing an enhancement of the interaction between the PBD and 
phosphopeptide substrates. The binding of FM00204 displaces the binding of a probe to the ATP-
binding site and does not affect a Plk1 protein mutated at the ATP-binding site. Therefore, we 
conclude that FM00204 binds at the ATP-binding site in the active conformation, like BI6727, 
Our study suggests that FM00204 inhibits Plk1 cellular functions mainly by affecting its proper 
dynamic location, enhancing the PBD interaction with phosphoproteins. FM00204 does not bind 
with high affinity. Therefore, in the right section of the panel we propose that upon the release of 
FM00204, Plk1 would have the ability to bind ATP and phosphorylate the PBD-mediated co-
localized substrates. (C) AW00551 binds to the catalytic domain of Plk1 and to the PBD of Plk1, 
inhibits the interaction of the PBD with phosphopeptides, stabilizing the close-inactive structure. 
In addition, the binding of AW00551 to the catalytic domain of Plk1 competes out the probe at 
the ATP-binding site. Based on the data obtained, we suggest that AW00551 makes interactions 
with both the catalytic domain and the PBD, stabilizing the closed-inactive structure of Plk1, 
where the PBD interacts with the catalytic domain and the ATP is in an inactive conformation. In 
the closed-inactive conformation, the PBD occludes part of the ATP-binding site. Therefore, the 
binding site of AW00551 could be at an interface between the catalytic domain and the PBD 
shown in option 1 or alternatively AW00551 could also bind at the inactive structure of the ATP-
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binding site as depicted in the cartoon shown in option 2. It is proposed that once Plk1 has lost its 
proper dynamic location in the cell, the release of an inhibitor with such mechanism of action (i.e. 
SCR01010) would not enable Plk1 to regain its physiological activity towards substrates (right 
section of the panel). 
 
Figure 4. Impact of SCR01010 and FM00204 on Plk1 and its interacting proteins in cells. (A) 
The representative quantification of the cell cycle analysis by FACS showing cells treated for 24 
h with compounds. (B) (left panel) Cells were treated followed by immunoblotting of the lysates 
for Plk1, Bora, Cyclin B1, and β-Actin. (right panel) Immunoprecipitation of Plk1 from 
asynchronous, SCR01010 and FM00204-treated cells. Plk1-interacting proteins were analyzed 
using western blot for Plk1, pT210 and Bora. (C) Cells were treated followed by immunoblotting 
of the lysates for pMyt1, phosho-Cdc25C (pcdc25C), Cdc25C, pTCTP, TCTP,bPlk1, Cyclin B1, 
phosho-Histone H3 (pH3), and β-Actin. 
Figure 5. The allosteric inhibitors FM00204 and SCR01010 interfere with Plk1´s subcellular 
localization in mitosis, generate aberrant and multipolar spindles, as well as an increase in 
chromosomal congression failure. HeLa cell were treated overnight with 25 µM Poloxin, 100 nM 
BI6727, 25 µM SCR01010 and 25 µM FM00240. Cells were fixed and prepared for 
immunofluorescence. (A) In order to assess the spindle phenotypes induced by the allosteric Plk1 
inhibitors, HeLa cells were fixed and stained for Plk1, α-tubulin, ACA (anti-centromere 
antibodies) and DNA. Examples of inhibitor dependent spindle phenotypes are shown (scale bar= 
10 µm). (B) The mitotic indices within the different treatment groups were scored by microscopy 
using DAPI staining. The results are presented as means ± SD (n = 400-600 cells). (C) 
Frequencies of cells with abnormal spindle formation. The results are represented as means ± SD 
(n = 300-400 cells). (D) The proportion of cells showing multipolar spindle. The results are 
represented as means ± SD (n = 300-400 cells). (E) The rate of cells presenting monopolar 
spindles in the different treatment groups. The results are represented as means ± SD (n = 300-
400 cells). (F) The percentages of chromosome congression failure were defined microscopically 
using DAPI and represented graphically. The results are represented as means ± SD (n = 300-400 
cells). (G) Examples of cells displaying Plk1 displacement from centrosome/kinetochore upon 
treatment with the inhibitors. -tubulin and ACA were considered as marker for centrosome and 
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kinetochore respectively (scale bar= 10 µM). (H) Quantification of Plk1 displacement from 
centrosome/kinetochore upon treatment with the allosteric inhibitors. The results are showed as 
means ± SD (n = 300-400 cells). 
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